Uniwersytet Lodzki

Ida Franiak-Pietryga

Dietmar Appelhans

Maria Bryszewska

Barbara Klajnert-Maculewicz

The subject matter of the invention relates to the method of administering the polypropyleneimine dendrimer of the fourth generation, coated with maltotriose, of a general formula I, wherein 25 to 45% of R substituents stand for a maltotriose residue and each of the remaining R substituents is H, to a human subject. The dendrimer of the formula I is designated in short as PPI-G4-OS-Mal-III, where PPI-G4 stands for the 4th generation of polypropyleneimine dendrimer, OS (Open Shell)&#x2014;for open coat, Mal-III for maltotriose (trisaccharide made of 3 &#x3b1;-glucose residues).

Application of maltotriose-coated 4th generation poly(propyleneimine) dendrimer PPI-G4-OS-Mal-III

The application of maltotriose-coated 4th generation polypropyleneimine dendrimer PPI-G4-OS-Mal-III containing 25-45% of peripheral amines groups coated with maltotriose particles to make a drug for treating neoplastic proliferation diseases, particularly chronic lymphocytic leukemia.

Growing community of inventors

San Diego, CA, United States of America

Ida Franiak-Pietryga